# Azido-PEG5-CH2CO2H

Cat. No.:	HY-130194	
CAS No.:	217180-81-9	
Molecular Formula:	C <sub>12</sub> H <sub>23</sub> N <sub>3</sub> O <sub>7</sub>	
Molecular Weight:	321.33	
Target:	ADC Linker; PROTAC Linkers	
Pathway:	Antibody-drug Conjugate/ADC Related; PROTAC	
Storage:	-20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)	

## SOLVENT & SOLUBILITY

Preparin	DMSO : 100 mg/mL (311.21 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	3.1121 mL	15.5603 mL	31.1207 mL		
		5 mM	0.6224 mL	3.1121 mL	6.2241 mL		
		10 mM	0.3112 mL	1.5560 mL	3.1121 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.78 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.78 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.78 mM); Clear solution						

BIOLOGICAL ACTIVITY					
Description	Azido-PEG5-CH2CO2H is a cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido- PEG5-CH2CO2H is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs <sup>[1]</sup> . Azido-PEG5-CH2CO2H is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.				
IC <sub>50</sub> & Target	Cleavable Linker	PEGs			
In Vitro	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker $^{[1]}$ .				

# Inhibitors • Screening Libraries • Proteins

о Ц<sub>он</sub>

\_0\_

\_0\_

<sup>-</sup>N<sup>2</sup>N<sup>\*</sup><sub>2</sub>N

\_0\_



PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Yong Zu Kim, et al. Antibody-drug conjugates comprising branched linkers and methods related thereto. WO2017089895A1.

### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA